Project TWENTY21

The PCCN is proud to be supporting Project Twenty21 in association with Drug Science, one of the most prominent research projects on medical cannabis in the United Kingdom. 

 

 

As a large-scale medical cannabis registry, the project aims to provide evidence for NHS funding where the benefits of treatment with medicinal cannabis is proven to outweigh the potential risks.

 

 

 

Project Twenty21 is a registry aiming to monitor the health outcomes of 20,000 patients using cannabis based medicinal products (CBMPs), creating the largest body of evidence in Europe for the safety and efficacy of CBMPs.

This real-world registry aims to target the following indications:

 

  • Anxiety Disorder
  • Chronic Pain
  • Multiple Sclerosis (MS)
  • Post-Traumatic Stress Disorder (PTSD)
  • Substance Use Disorder (as a harm reduction strategy)
  • Tourette’s Syndrome
  • Epilepsy – coming soon in 2021

 

 

Treatment is provided at a network of private clinics across the UK which utilise best-practice in medical cannabis treatment. Click here to see the list of clinics.

 

 

Any doctor on GMC Specialist Register can prescribe medical cannabis – this is usually a hospital consultant. Although a GP can prescribe under shared care arrangements under the direction of a specialist, we find that most NHS Clinic Commissioning Groups (CCGs) prefer not to issue prescriptions from private clinics.

 

More information for prescribers can be found here 

 

Project Twenty21 has the support  of The Royal College of Psychiatrists, The British Pain Society, PLEA, patients, peers and medical cannabis campaigners.